Hospital
Dignity Health
Dignity Health was paid $8.52M by Medicaid between Jan 2018 and Dec 2024, across 156 billing codes. Its largest line is 99284, emergency room visit (serious) — 22% of everything it billed.
33Billing provider infoDIGNITY HEALTH
HENDERSON, NV 89015
HENDERSON, NV 89015
33aNPI1447393152assigned 02/14/2007
33bProvider typeRehabilitation Hospital Unit
28Total paid$8.52M
24GClaims443,126
24DCodes billed156
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MORISSETTE, DANIEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 53,157 | $787K | |
| 2019 | 89,383 | $1.55M | |
| 2020 | 60,641 | $1.22M | |
| 2021 | 68,091 | $1.28M | |
| 2022 | 65,098 | $1.35M | |
| 2023 | 60,900 | $1.30M | |
| 2024incomplete | 45,856 | $1.03M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 24,291 | 20,252 | $1.89M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 17% | 12,768 | 10,385 | $1.41M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 26,499 | 22,960 | $1.28M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 9.6% | 3,913 | 3,273 | $822K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.8% | 3,364 | 2,818 | $238K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.8% | 1,796 | 1,550 | $235K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.7% | 14,292 | 11,354 | $229K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 5,369 | 4,812 | $184K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.7% | 12,293 | 9,512 | $147K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.6% | 5,738 | 4,669 | $138K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.5% | 612 | 496 | $127K |
| 80053 | Comprehensive metabolic panel | 1.4% | 25,567 | 20,298 | $121K |
144 more codes
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.0% | 5,786 | $88K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 27,797 | $86K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 5,276 | $76K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,821 | $70K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,042 | $69K |
| 71045 | Radiologic examination, chest; single view | <1% | 11,529 | $67K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 275 | $59K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 12,924 | $51K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 584 | $49K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,706 | $49K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,320 | $47K |
| 83880 | <1% | 4,495 | $46K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,587 | $44K |
| J3490 | Unclassified drugs | <1% | 11,271 | $41K |
| 84484 | <1% | 9,721 | $35K | |
| 83690 | <1% | 12,527 | $35K | |
| 84703 | <1% | 10,143 | $34K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,418 | $33K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,842 | $33K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,843 | $33K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,909 | $32K |
| 87040 | <1% | 3,471 | $29K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 716 | $28K |
| 0450 | Emergency room services | <1% | 699 | $26K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,818 | $22K |
| 36415 | Collection of venous blood by venipuncture | <1% | 21,082 | $20K |
| 96376 | <1% | 2,434 | $20K | |
| 83605 | <1% | 4,659 | $20K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,016 | $19K |
| 90715 | <1% | 665 | $19K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,872 | $19K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 352 | $19K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,044 | $16K |
| 81001 | <1% | 10,674 | $13K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 982 | $13K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 206 | $13K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,672 | $12K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,124 | $12K |
| 73610 | <1% | 601 | $11K | |
| 76801 | <1% | 193 | $11K | |
| 74022 | <1% | 553 | $11K | |
| 85379 | <1% | 2,528 | $11K | |
| 73630 | <1% | 679 | $10K | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,946 | $10K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,455 | $10K |
| 87088 | <1% | 2,958 | $10K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 556 | $9K |
| 73030 | <1% | 579 | $9K | |
| 72131 | <1% | 87 | $9K | |
| G0378 | Hospital observation service, per hour | <1% | 341 | $9K |
| 81025 | <1% | 2,759 | $9K | |
| 85610 | <1% | 6,754 | $9K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,434 | $8K |
| 85730 | <1% | 4,107 | $8K | |
| 10060 | <1% | 131 | $8K | |
| 76830 | Ultrasound, transvaginal | <1% | 109 | $7K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,113 | $7K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,595 | $6K |
| 70486 | <1% | 46 | $6K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 916 | $6K |
| 82550 | <1% | 2,772 | $6K | |
| 85027 | <1% | 2,082 | $6K | |
| 84702 | <1% | 779 | $6K | |
| 73130 | <1% | 291 | $5K | |
| 94644 | <1% | 343 | $5K | |
| J1815 | Injection, insulin, per 5 units | <1% | 292 | $5K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 780 | $5K |
| 93971 | <1% | 104 | $4K | |
| 83735 | <1% | 1,923 | $4K | |
| 73110 | <1% | 188 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,459 | $4K |
| 81003 | <1% | 4,420 | $4K | |
| 73564 | <1% | 140 | $4K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 78 | $3K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 317 | $3K |
| 87077 | <1% | 901 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,160 | $3K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 558 | $2K |
| 82962 | <1% | 2,365 | $2K | |
| 87081 | <1% | 682 | $2K | |
| 86703 | <1% | 316 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,933 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,328 | $2K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 719 | $2K |
| 87210 | <1% | 735 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 368 | $1K |
| 73562 | <1% | 71 | $1K | |
| 12001 | <1% | 42 | $1K | |
| 72100 | <1% | 89 | $1K | |
| 29125 | <1% | 46 | $1K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 734 | $1K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 932 | $1K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 20 | $993.23 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 128 | $900.32 |
| 71101 | <1% | 48 | $816.22 | |
| 99070 | <1% | 53 | $773.57 | |
| 80320 | <1% | 1,565 | $751.50 | |
| 90658 | <1% | 121 | $741.66 | |
| 86901 | <1% | 587 | $720.21 | |
| 86140 | <1% | 333 | $692.93 | |
| 86592 | <1% | 316 | $682.44 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 136 | $624.07 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 134 | $556.48 |
| 82803 | <1% | 85 | $496.19 | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 19 | $430.78 |
| 82330 | <1% | 87 | $378.70 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 17 | $359.25 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 208 | $341.37 |
| 80329 | <1% | 426 | $298.05 | |
| 87631 | <1% | 222 | $284.40 | |
| 73080 | <1% | 17 | $214.80 | |
| 85007 | <1% | 243 | $191.93 | |
| 82553 | <1% | 93 | $185.74 | |
| 84145 | <1% | 12 | $149.81 | |
| 80076 | <1% | 47 | $104.18 | |
| 85014 | <1% | 254 | $103.68 | |
| 80047 | <1% | 35 | $86.55 | |
| 85652 | <1% | 73 | $83.25 | |
| 82728 | <1% | 14 | $74.40 | |
| 86850 | <1% | 45 | $65.28 | |
| 84100 | <1% | 33 | $64.22 | |
| 84132 | <1% | 107 | $59.66 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 85 | $55.43 |
| 86900 | <1% | 46 | $47.07 | |
| 87147 | <1% | 14 | $45.97 | |
| 84295 | <1% | 85 | $45.92 | |
| 82947 | <1% | 83 | $45.56 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 41 | $43.74 |
| 84439 | <1% | 14 | $43.05 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 21 | $39.60 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 31 | $39.50 |
| J0456 | Injection, azithromycin, 500 mg | <1% | 31 | $39.48 |
| 82010 | <1% | 18 | $39.06 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 61 | $28.97 |
| 99406 | <1% | 76 | $20.82 | |
| 80061 | Lipid panel | <1% | 78 | $14.93 |
| 80069 | <1% | 22 | $6.08 | |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 20 | $0.09 |
| A9270 | Non-covered item or service | 0% | 3,467 | $0.00 |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 43 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 38 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 38 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 73 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 72 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORISSETTE, DANIEL (CHIEF FINANCIAL OFFICER)
Parent organizationDIGNITY HEALTH
| Provider | Location | Paid |
|---|---|---|
| Dignity Health | San Bernardino, CA | $133.09M |
| Dignity Health | Phoenix, AZ | $126.19M |
| Dignity Health | Bakersfield, CA | $109.22M |
| Dignity Health | Merced, CA | $106.54M |
| Dignity Health | Carmichael, CA | $97.28M |
| Dignity Health | Oxnard, CA | $96.24M |
| Dignity Health | Redding, CA | $92.21M |
| Dignity Health | Long Beach, CA | $59.98M |
| Dignity Health | Sacramento, CA | $45.52M |
| Dignity Health | Folsom, CA | $45.14M |
| Dignity Health | Red Bluff, CA | $39.92M |
| Dignity Health | Santa Cruz, CA | $33.59M |
| Dignity Health | Gilbert, AZ | $28.49M |
| Dignity Health | Glendale, AZ | $26.30M |
| Dignity Health | Henderson, NV | $18.73M |
| Dignity Health | Mount Shasta, CA | $15.62M |
| Dignity Health | Las Vegas, NV | $7.93M |
| Dignity Health | Camarillo, CA | $6.31M |
| Dignity Health | Santa Maria, CA | $5.79M |
| Dignity Health | Corning, CA | $3.24M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.